Table 1.
Clinical characteristics in the younger cohort receiving chemotherapy and the elderly cohort receiving hypomethylating agents according to RUNX1 mutation status.
| Clinical Characteristics | Younger Cohort (Chemotherapy) | p-Value | Elderly Cohort (HMA) | p-Value | ||
|---|---|---|---|---|---|---|
| Median (Range) | Median (Range) | |||||
| RUNX1mut | RUNX1WT | RUNX1mut | RUNX1WT | |||
| (n = 9) | (n = 168) | (n = 24) | (n = 127) | |||
| Age, year | 56 (31–63) | 51 (17–64) | 0.14 | 77 (65–92) | 73 (65–91) | 0.01 * |
| WBC, ×109/L | 4.95 (1.3–17.2) | 6.9 (0.5–378.4) | 0.43 | 3.2 (0.6–36.5) | 3.2 (0.3–164.5) | 0.98 |
| Platelet count, ×109/L | 57.5 (28–213) | 30 (1–584) | 0.05 | 61 (7–416) | 42 (3–324) | 0.20 |
| Hemoglobin, g/dL | 8.95 (7.4–12.1) | 9.3 (5.1–13.0) | 0.38 | 9.4 (5.8–13.1) | 9.4 (7.5–13.2) | 0.37 |
| Peripheral blood blasts, % | 28 (1–86) | 25.5 (0–97) | 0.61 | 7 (0–90) | 11 (0–95) | 0.51 |
| Neutrophils, % | 14.5 (0–45) | 12 (0–98) | 0.93 | 21 (0–81) | 21 (0–73.3) | 0.95 |
| Bone marrow blasts, % | 51 (28–93) | 54 (2–96) | 0.66 | 50 (12–84) | 44 (1–90) | 0.80 |
| Cytogenetic | 0.94 | 0.02 | ||||
| Complex | 2 | 37 | 2 | 47 | ||
| Diploid | 3 | 65 | 14 | 50 | ||
| ^ Intermediate | 4 | 66 | 8 | 30 | ||
| LDH, U/L | 668.5 | 888 | 0.10 | 532 | 650 | 0.44 |
| (526–1649) | (310–12,489) | (276–2314) | (210–3921) | |||
| t-AML | 0 | 10 | 0.45 | 4 | 18 | 0.75 |
| Prior MDS/MPD | 1 | 6 | 0.26 | 8 | 25 | 0.14 |
Abbreviations: LDH, lactate dehydrogenase; HMA, hypomethylating agent; Prior MDS/MPD: Prior myelodysplastic syndrome or myeloproliferative neoplasms; t-AML, therapy-related acute myeloid leukemia; WBC, white blood cell; * Boldface indicates statistical significance. ^ Intermediate also includes insufficient metaphases and not done.